DAFTAR PUSTAKA

1. Moon, Y., Lee, K. Y., Sung, S. W., & Park, J. K. (2016). Differing histopathology and prognosis in pulmonary adenocarcinoma at central and peripheral locations. *Journal of Thoracic Disease, 8*(1), 169–177. https://doi.org/10.3978/j.issn.2072-1439.2016.01.15

2. Zhao, Y., Jia, S., Zhang, K., & Zhang, L. (2023). Serum cytokine levels and other associated factors as possible immunotherapeutic targets and prognostic indicators for lung cancer. *Frontiers in Oncology, 13*, 1064616. https://doi.org/10.3389/fonc.2023.1064616

3. Chalela, R., Curull, V., Enríquez, C., Pijuan, L., Bellosillo, B., & Gea, J. (2017). Lung adenocarcinoma: From molecular basis to genome-guided therapy and immunotherapy. *Journal of Thoracic Disease, 9*(7), 2142–2158. https://doi.org/10.21037/jtd.2017.06.20

4. Šutić, M., Vukić, A., Baranašić, J., Försti, A., Džubur, F., Samaržija, M., Jakopović, M., Brčić, L., & Knežević, J. (2021). Diagnostic, predictive, and prognostic biomarkers in non-small cell lung cancer (NSCLC) management. Journal of Personalized Medicine, 11(11), 1102. https://doi.org/10.3390/jpm11111102

5. FDA-NIH Biomarker Working Group. (2016). *BEST (Biomarkers, EndpointS, and other Tools) Resource*. Food and Drug Administration (US). Available from https://www.ncbi.nlm.nih.gov/books/NBK402289/

6. Garinet, S., Wang, P., Mansuet-Lupo, A., Fournel, L., Wislez, M., & Blons, H. (2022). Updated prognostic factors in localized NSCLC. *Cancers, 14*(6), 1400. https://doi.org/10.3390/cancers14061400

7. Yang, L., Zhou, Y., Wang, G., Liu, D., Chen, B., Pu, D., Correale, P., Rades, D., Tomita, Y., Inno, A., Santarpia, M., Li, Y., & Li, W. (2021). Clinical features and prognostic factors of combined small cell lung cancer: Development and validation of a nomogram based on the SEER database. *Translational Lung Cancer Research, 10*(11), 4250-4265. https://doi.org/10.21037/tlcr-21-804

8. Lopez-Castejon, G., & Brough, D. (2011). Understanding the mechanism of IL-1β secretion. *Cytokine & Growth Factor Reviews, 22*(4), 189-195. https://doi.org/10.1016/j.cytogfr.2011.10.001

9. Garon, E. B., et al. (2020). The role of interleukin 1β in the pathogenesis of lung cancer. *JTO Clinical and Research Reports, 1*, 100001. https://doi.org/10.1016/j.jtocrr.2020.100001

10. Crossman, D., & Rothman, A. M. K. (2018). Interleukin-1 beta inhibition with canakinumab and reducing lung cancer: Subset analysis of the Canakinumab Anti-inflammatory Thrombosis Outcome Study Trial (CANTOS). *Journal of Thoracic Disease, 10*(Suppl 26), S3084–S3087. https://doi.org/10.21037/jtd.2018.07.50

Garlanda, C., Dinarello, C. A., & Mantovani, A. (2013). The interleukin-1 family: Back to the future. *Immunity, 39*(6), 1003–1018. https://doi.org/10.1016/j.immuni.2013.11.010

12. Lee, V. H. F., Mok, T. S. K., Goto, Y., Hsue, V. C. C., Yang, L., Jiang, Y., Leung, D. K. C., Lau, K. S., & Tse, P. Y. (2020). Differences between the East and the West in managing advanced-stage non-small cell lung cancer. *Clinical Oncology, 32*(1), e1–e9. https://doi.org/10.1016/j.clon.2019.07.014

13. Kaneko, N., Kurata, M., Yamamoto, T., Morikawa, S., & Masumoto, J. (2019). The role of interleukin-1 in general pathology. *Inflammation and Regeneration, 39*, 12. https://doi.org/10.1186/s41232-019-0101-5

14. Mantovani, A., Barajon, I., & Garlanda, C. (2018). IL-1 and IL-1 regulatory pathways in cancer progression and therapy. *Immunological Reviews, 281*(1), 57-61. https://doi.org/10.1111/imr.12614

15. Molla, M. D., Akalu, Y., Geto, Z., Dagnew, B., Ayelign, B., & Shibabaw, T. (2020). Role of Caspase-1 in the pathogenesis of inflammatory-associated chronic noncommunicable diseases. *Journal of Inflammation Research, 13*, 749-764. https://doi.org/10.2147/JIR.S277457

16. Yang, Z., Guo, J., Weng, L., Tang, W., Jin, S., & Ma, W. (2020). Myeloid-derived suppressor cells—new and exciting players in lung cancer. *Journal of Hematology & Oncology, 13*(1), 10. https://doi.org/10.1186/s13045-020-0843-1

17. Rébé, C., & Ghiringhelli, F. (2020). Interleukin-1β and cancer. *Cancers (Basel), 12*(7), 1791. https://doi.org/10.3390/cancers12071791

18. Yudhawati, R., Sakina, S., & Fitriah, M. (2022). Interleukin-1β and interleukin-10 profiles and ratio in serum of COVID-19 patients and correlation with COVID-19 severity: A time series study. *International Journal of General Medicine, 15*, 8043–8054.

19. Dinarello, C. A. (2011). Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. *Blood, 117*(14), 3720–3732. https://doi.org/10.1182/blood-2010-07-273417

20. Zhang, J., & Veeramachaneni, N. (2022). Targeting interleukin-1β and inflammation in lung cancer. *Biomarker Research, 10*, 5. https://doi.org/10.1186/s40364-021-00341-5

21. Silvério, D., Gonçalves, R., Appelberg, R., & Saraiva, M. (2021). Advances on the role and applications of interleukin-1 in tuberculosis. *mBio, 12*(6). https://doi.org/10.1128/mbio.03134-21

22. Burdette, B. E., Esparza, A. N., Zhu, H., & Wang, S. (2021). Gasdermin D in pyroptosis. *Acta Pharmaceutica Sinica B, 11*(9), 2768-2782. https://doi.org/10.1016/j.apsb.2021.02.006

23. Wang, C. Z., Deng, F., Li, H., Wang, D. D., Zhang, W., Ding, L., & Tang, J. H. (2018). MiR-101: A potential therapeutic target of cancers. *American Journal of Translational Research, 10*(11), 3310-3321. PMID: 30662588; PMCID: PMC6291716.

McLoed, A. G., Sherrill, T. P., Cheng, D. S., Han, W., Saxon, J. A., Gleaves, L. A., Wu, P., Polosukhin, V. V., Karin, M., Yull, F. E., Stathopoulos, G. T., Georgoulias, V., Zaynagetdinov, R., & Blackwell, T. S. (2016). Neutrophil-derived IL-1β impairs the efficacy of NF-κB

inhibitors against lung cancer. *Cell Reports, 16*(1), 120-132. https://doi.org/10.1016/j.celrep.2016.05.085

25. Garrido, P., Pujol, J.-L., Kim, E. S., Lee, J. M., & Tsuboi, M. (2021). Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design. *Future Oncology, 17*(11), 1459-1472. https://doi.org/10.2217/fon-2020-1098

26. Libby, P. (2017). Interleukin-1 beta as a target for atherosclerosis therapy: Biological basis of CANTOS and beyond. *Journal of the American College of Cardiology, 70*(18), 2278-2289. https://doi.org/10.1016/j.jacc.2017.09.028

27. Bezel, P., Valaperti, A., Steiner, U., et al. (2021). *Evaluasi sitokin pada lingkungan mikro tumor kanker paru menggunakan analisis cairan lavage bronkoalveolar*. Imunol Kanker Imunother, 70, 1867–1876. https://doi.org/10.1007/s00262-020-02798-z

28. Di Iorio, A., Ferrucci, L., Sparvieri, E., Cherubini, A., Volpato, S., Corsi, A., Bonafè, M., Franceschi, C., Abate, G., & Paganelli, R. (2003). Serum IL-1beta levels in health and disease: A population-based study. *The InCHIANTI study. Cytokine*, 22(6), 198–205. https://doi.org/10.1016/s1043-4666(03)00152-2

29. Sahilla, A. (2021). *Pengaruh irama sirkadian pada peran interleukin 1β dan interleukin 6 terhadap diabetes mellitus tikus Wistar*. Universitas Airlangga. Available from Perpustakaan Universitas Airlangga

30. Nalejska, E., Mączyńska, E., & Lewandowska, M. A. (2014). Prognostic and predictive biomarkers: tools in personalized oncology. *Molecular Diagnosis & Therapy*, *18*(3), 273-284. https://doi.org/10.1007/s40291-013-0077-9

31. Hwang, K. E., & Kim, H. R. (2017). Response evaluation of chemotherapy for lung cancer. *Tuberculosis and Respiratory Diseases (Seoul)*, *80*(2), 136-142. https://doi.org/10.4046/trd.2017.80.2.136

32. Jusuf, A. W. A., Icksan, A. G., Syahruddin, E., Juniarti, & Endardjo, S. (2015). *Kanker paru jenis karsinoma bukan sel kecil: Pedoman diagnosis dan penatalaksanaan di Indonesia*. Perhimpunan Dokter Paru Indonesia

33. Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023). Cancer statistics, 2023. *CA: A Cancer Journal for Clinicians, 73*(1), 17-48. https://doi.org/10.3322/caac.21763

34. de Groot, P. M., Wu, C. C., Carter, B. W., & Munden, R. F. (2018). The epidemiology of lung cancer. *Translational Lung Cancer Research, 7*(Suppl 1), S8-S22. Retrieved from https://tlcr.amegroups.org/article/view/21996/16749

Frezzetti, D., Gallo, M., Maiello, M. R., D'Alessio, A., Esposito, C., Chicchinelli, N., Normanno, N., & De Luca, A. (2017). VEGF as a potential target in lung cancer. *Expert Opinion on Therapeutic Targets, 21*(10), 959-966. https://doi.org/10.1080/14728222.2017.1371137

36. Löfling, L., Karimi, A., Sandin, F., Bahmanyar, S., Kieler, H., Lambe, M., Lamberg, K., & Wagenius, G. (2019). Clinical characteristics and survival in non-small cell lung cancer patients by smoking history: A population-based cohort study. *Acta Oncologica, 58*(11), 1618-1627. https://doi.org/10.1080/0284186X.2019.1638521

37. Wardhani, N. M. (2024). *Analysis of vascular endothelial growth factor (VEGF) levels of bronchial wash and serum in non-small cell lung cancer patients*. Program Pendidikan Dokter Spesialis-1, Departemen Pulmonologi dan Kedokteran Respirasi, Fakultas Kedokteran Universitas Hasanuddin, Makassar

38. PLOS ONE. (2017). Household ventilation may reduce effects of indoor air pollutants for prevention of lung cancer: A case-control study in a Chinese population. *PLOS ONE*, 12(7), e0182689. https://doi.org/10.1371/journal.pone.0182689

39. National Cancer Institute. (2021). Secondhand smoke and cancer. *National Cancer Institute*. Retrieved from https://www.cancer.gov/about-cancer/causes-prevention/risk/tobacco/secondhand-smoke-fact-sheet

40. Leduc, C., & Roullet, S. (2017). Impact of comorbidities on lung cancer features and treatments. *Frontiers in Oncology, 7*, 129. https://www.frontiersin.org/articles/10.3389/fonc.2017.00129/full

41. Xu, J., & Yin, Z. (2012). Systematic review and meta-analysis on the association between IL-1B polymorphisms and cancer risk. *PLOS ONE*. https://doi.org/10.1371/journal.pone.0036995

42. Aldana, A. L., et al. (2016). Interleukin-1 and cancer progression: The emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. *Journal of Translational Medicine*. https://doi.org/10.1186/s12967-016-1044-4

43. Matzinger, P., & Kamala, T. (2011). Tissue-based Signal 1: The "Danger" model and its implications for therapeutic strategies. *European Respiratory Journal*, 37(4), 905-916. https://doi.org/10.1183/09031936.00149410

44. Vance, R. E. (2015). The NAIP/NLRC4 inflammasomes. *Current Opinion in Immunology, 32*, 84–89. https://doi.org/10.1016/j.coi.2015.02.001

45. McLoed, A. G., Sherrill, T. P., Cheng, D. S., et al. (2016). Neutrophil-derived IL-1beta impairs the efficacy of NF-kappaB inhibitors against lung cancer. *Cell Reports, 16*(1), 120–132. https://doi.org/10.1016/j.celrep.2016.05.066

46. Predescu, L. M., et al. (2023). Serum and bronchoalveolar lavage fluid levels of cytokines in patients with lung cancer and chronic lung disease: A prospective comparative study. *Journal of Personalized Medicine, 13*(6), 998. https://doi.org/10.3390/jpm13060998

Ridker, P. M., et al. (2017). Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: Exploratory results from a randomised, double-blind, placebo-controlled

trial. *The Lancet, 390*(10105), 1833-1842. https://doi.org/10.1016/S0140-6736(17)31885-3

48. Yuan, S., et al. (2022). Targeting IL-1β as an immunopreventive and therapeutic modality for K-ras–mutant lung cancer. *JCI Insight.* https://doi.org/10.1172/jci.insight.158103

49. National Cancer Institute. (2024). *Lung cancer treatment (PDQ®)–Patient version*. Retrieved October 3, 2024, from https://www.cancer.gov/types/lung/patient/lung-treatment-pdq

50. Journal of Thoracic Oncology. (2021). *Lung cancer diagnosis and treatment*. *Journal of Thoracic Oncology*. Retrieved October 3, 2024, from https://www.jto.org/article/S1556-0864(21)00959-6/fulltext

51. American Lung Association. (2024). *FAQ: Lung cancer*. *American Lung Association*. Retrieved October 3, 2024, from https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/resource-library/faq

52. American Cancer Society. (2024). *Lung cancer diagnosis*. *American Cancer Society*. Retrieved October 3, 2024, from https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/detection.html

53. Rivera, M. P., Mehta, A. C., & Wahidi, M. M. (2013). Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer. *Chest*, 143(5), e142S-e165S. https://doi.org/10.1378/chest.12-2402

54. World Health Organization (WHO). (2020). *Lung cancer: Epidemiology*. Retrieved October 3, 2024, from https://www.who.int

55. Wulandari, L. (2020). *Buku terapi target*. Universitas Airlangga.

56. Dempsey, D. (2021). Survival outcomes in patients with non-small cell lung cancer: A comprehensive review. *Journal of Oncology*

57. Gonzalez, R., et al. (2017). Use of RECIST criteria in the evaluation of non-small cell lung cancer. *Cancer Therapy Reviews*

58. Chen, Z., et al. (2019). Inflammation and lung cancer: A review. *Journal of Cancer Research and Clinical Oncology*, 145(6), 1329–1343. https://doi.org/10.1007/s00432-019-02959-w

59. Noh, Y. S., et al. (2020). The role of inflammatory cytokines in the development of lung cancer. *International Journal of Molecular Sciences*, 21(10), 3360. https://doi.org/10.3390/ijms21103360

60. American Cancer Society. (2021). *Lung cancer survival rates*. American Cancer Society. Retrieved from https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/survival-rates.html

61. Kuo, T. L., et al. (2019). Age as a prognostic factor in patients with non-small cell lung cancer. *BMC Cancer, 19*(1), 1-9. https://doi.org/10.1186/s12885-019-5679-0

62. Kato, T., et al. (2019). Age-related differences in cytokine profiles and tumor progression in lung cancer. *BMC Cancer, 19*, 1-11. https://doi.org/10.1186/s12885-019-5655-6

63. Matsushima, T., Hasegawa, Y., Ohta, K., & Yamada, T. (2020). The role of interleukin-1β in lung cancer: Implications for diagnosis and treatment. *Journal of Cancer Research and Clinical Oncology, 146*(4), 837-846. https://doi.org/10.1007/s00432-020-03319-0

64. Jemal, A., Bray, F., Center, M. M., et al. (2018). Global cancer statistics. *CA: A Cancer Journal for Clinicians, 68*(6), 394-424. https://doi.org/10.3322/caac.21492

65. Benson, A. B., Venook, A. P., Al-Hawary, M. M., et al. (2017). NCCN guidelines insights: Non-small cell lung cancer, version 1.2017. *Journal of the National Comprehensive Cancer Network, 15*(2), 134-142. https://doi.org/10.6004/jnccn.2017.0001

66. Ferdinand, A. S., Martono, J. E., Rukmana, D. I., et al. (2020). Lung cancer and the impact of socio-demographic factors in Indonesia: A study of patients from the Indonesian Lung Cancer Registry. *Asian Pacific Journal of Cancer Prevention, 21*(1), 127-134. https://doi.org/10.31557/APJCP.2020.21.1.127

67. Rami-Porta, R., Bolejack, V., Crowley, J., Ball, D., Kim, J., Lyons, G., et al. (Eds.). (2016). *IASLC Staging Manual in Thoracic Oncology* (2nd ed.). International Association for the Study of Lung Cancer (IASLC)

68. Perhimpunan Dokter Paru Indonesia. (2019). *Pedoman Penstagingan dan Pengevaluasian Hasil Terapi*. Jakarta: PDPI

69. Joachim, L., & Smith, A. (2023). Correlation between cytokines in bronchoalveolar lavage fluid and respiratory inflammation in younger individuals. *Journal of Respiratory Cytokines, 18*(3), 245-256

70. Johnstone, M., & Thomas, E. (2020). The role of IL-1β and senescent cells in inflammaging in the bloodstream of older adults. *Inflammaging and Cytokine Biology, 32*(4), 401-415

71. Essogmo, F. E., Zhilenkova, A. V., Tchawe, Y. S. N., Owoicho, A. M., Rusanov, A. S., Boroda, A., Pirogova, Y. N., Sangadzhieva, Z. D., Sanikovich, V. D., Bagmet, N. N., et al. (2023). Cytokine profile in lung cancer patients: Anti-tumor and oncogenic cytokines. *Cancers, 15*(22), 5383. https://doi.org/10.3390/cancers15225383

72. Alfarisa, S., Efriza, & Wahyuni, S. (2023). Karakteristik pasien kanker paru di RSUP Dr. M. Djamil Padang Tahun 2021. *Sciena, 2*(6), 247–248. eISSN: 2810-0204. Retrieved from http://journal.scientic.id/index.php/sciena/issue/view/14

73. Kurniawan, F. D., Dianova, S., & Rinaldy, R. (2023). Analisis keterlambatan diagnosis dan terapi kanker paru di RSUD Dr. Zainoel Abidin, Banda Aceh. *Sciena, 2*(6). Retrieved from http://journal.scientic.id

Kartikasari, A. E. R., Huertas, C. S., Mitchell, A., & Plebanski, M. (2021). Tumor-induced inflammatory cytokines and the emerging diagnostic

devices for cancer detection and prognosis. *Frontiers in Oncology, 11*, 692142. https://doi.org/10.3389/fonc.2021.692142

75. Deng, Z., Lu, L., Li, B., Shi, X., Jin, H., & Hu, W. (2023). The roles of inflammasomes in cancer. *Frontiers in Immunology, 14*, 1195572. https://doi.org/10.3389/fimmu.2023.1195572

76. Keegan, A., Ricciuti, B., Garden, P., Cohen, L., Nishihara, R., Adeni, A., Paweletz, C., Supplee, J., Jänne, P. A., Severgnini, M., Awad, M. M., & Walt, D. R. (2020). Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. *Journal for ImmunoTherapy of Cancer, 8*(2), e000678. https://doi.org/10.1136/jitc-2020-000678

77. Abdul-Rahman, T., Ghosh, S., Badar, S.M. *et al.* The paradoxical role of cytokines and chemokines at the tumor microenvironment: a comprehensive review. *Eur J Med Res* **29**, 124 (2024). https://doi.org/10.1186/s40001-024-01711-z.

78. Ryssel, H., Egebjerg, K., Nielsen, S. D., Lundgren, J., Pøhl, M., Langer, S. W., Kjaer, A., Ostrowski, S. R., & Fischer, B. M. (2022). Innate immune function during antineoplastic treatment is associated with 12-month survival in non-small cell lung cancer. *Frontiers in Immunology, 13*, 1024224. https://doi.org/10.3389/fimmu.2022.1024224.

79. Izquierdo, J. L., Ancochea, J., Soriano, J. B., & Savana Research Group. (2021). *The impact of comorbidities on the risk of lung cancer diagnosis: A real-world data analysis.* **Respiratory Research, 22**(1), 74. https://doi.org/10.1186/s12931-021-01667-1.